In the novel EIDOS, the Great Transfer revolves around a single question:
“What part of a person must continue for us to say that they have not died?”
For millennia, immortality belonged to the realm of gods, myths and religions. Heroes searched for fountains of youth. Alchemists dreamed of an elixir able to stop decay. Civilizations imagined paradises, reincarnations, glorified bodies or eternal memories.
Today, for the first time, part of that question has left myth and entered the laboratory.
Not because science is close to guaranteeing human immortality. It is not. But because it is beginning to understand, with a precision that would have seemed impossible only a few decades ago, why we age, which mechanisms fail over time and which routes might delay, repair or even reverse part of that deterioration.
The question is no longer only philosophical.
Could we remain young for decades or centuries? Could we lengthen telomeres without causing cancer? Could we reprogram the epigenetic age of a cell without erasing its identity? Could we rejuvenate organs before transplanting them? Could we replace pieces of the body until natural death stops making sense? Could we freeze a brain and bring it back to life? Could we copy a mind into a virtual world?
The answer, as almost always in science, is not simple. But there are clues.
The problem that makes it necessary: death no longer looks like a single frontier
Modern medicine has learned to defeat many specific causes of death. Antibiotics, vaccines, surgery, anesthesia, transplants, chemotherapy, gene editing, intensive care, pacemakers, valves, stents, dialysis and immunotherapy. Each generation has pushed the boundary a little further.
Yet aging remains the great risk multiplier. It does not kill like an infection or an accident. It acts more slowly and more deeply: it increases the probability of almost everything else. Cancer. Cardiovascular disease. Alzheimer’s. Frailty. Type 2 diabetes. Kidney failure. Macular degeneration. Muscle loss. Immune decline.
That is why modern biogerontology has changed the frame. Instead of treating every age-related disease as a separate island, it begins to ask whether there is a common territory underneath all of them: the biological processes of aging.
In 2013, Carlos López-Otín and other researchers proposed the so-called hallmarks of aging, the major traits of aging. In 2023, an update expanded the map to twelve mechanisms: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem-cell exhaustion, altered intercellular communication, chronic inflammation and dysbiosis.
This changes the question.
We do not age because a single clock reaches zero. We age because damage, defective signals, dysfunctional cells, inflammation, repair errors, loss of coordination between tissues and changes in gene expression accumulate. The body does not shut down all at once. It loses order.
Biological immortality, if it ever existed, would not consist of fixing one piece. It would require intervening in an entire network without breaking the equilibrium that allows us to remain alive.
Old age is not a single disease. It is a network. And a network cannot be defeated by pulling one thread.
Bibliography for this section
The Hallmarks of Aging — Cell (2013)
Hallmarks of aging: An expanding universe — Cell (2023)
XPRIZE Healthspan — global healthy-longevity competition
Before the laboratories: the animals that seem not to age
Nature had already experimented with unusual ways of escaping aging long before humans tried to overcome it in gene-therapy laboratories.
One of the most cited examples is Hydra, a small freshwater animal capable of extraordinary regeneration. Some species maintain active stem-cell populations throughout life and show negligible senescence under controlled conditions. They are not invulnerable: they can die through predation, disease or environmental change. But they do not seem to follow the usual pattern of progressive deterioration that we associate with aging.
Another fascinating case is Turritopsis dohrnii, the so-called “immortal jellyfish.” When it suffers stress, physical damage or adverse conditions, it can revert from its adult phase to a polyp stage through cellular transdifferentiation. It does not live forever in the mythical sense: in nature it can be eaten or become ill. But its life cycle proves something unsettling: in some organisms, age is a state that can move backward.
These animals do not offer a direct recipe for human immortality. A hydra or a jellyfish is far simpler than a person, with no comparable brain, no autobiographical identity and no complex organs to maintain for decades. But they teach a decisive lesson: biology is not forced to age in the same way every time. Natural strategies of regeneration, plasticity and cellular renewal exist, and they break our intuition about life.
Longevity science is, in part, an attempt to translate that lesson to complex organisms: to understand which mechanisms allow tissues to repair without losing identity, cells to renew without generating cancer and function to last without disorganizing the body.
Escaping the Inevitability of Ageing — Current Biology
Regenerative characteristics of the immortal jellyfish — PubMed
First clue: Telomeres, a key piece of the biological clock: balancing possibilities, risks, and unanswered questions
For years, telomeres became one of the most famous images of aging. They are structures located at the ends of chromosomes, often compared to the little plastic caps that protect shoelaces. Their function is to protect DNA during cell division.
Every time a cell divides, those ends tend to shorten. When they become too short or are damaged, the cell can enter senescence, stop dividing or die. At first glance, the solution seems obvious: if telomeres shorten with age, let us lengthen them.
Here telomerase appears, an enzyme capable of rebuilding those ends. In some cells, such as germ cells, stem cells and many tumor cells, telomerase is active. In most adult somatic cells, it is not. That absence is a safety measure.
A young body needs regeneration. But a safe body needs limits.
The ability to divide many times can help repair tissues, but it can also allow damaged cells to escape their natural barriers. Many cancer cells reactivate telomere-maintenance mechanisms in order to divide without control. Seen up close, cellular immortality resembles a tumor property.
Research has not stopped there. In recent years, more precise strategies have been explored. One of the most striking is ZSCAN4, a gene associated with telomeric recombination processes. In 2025, Elixirgen Therapeutics published early results from an ex vivo gene therapy for telomere-biology disorders, with sustained telomere elongation in patients’ blood cells and no apparent toxicity in that small initial group.
This does not mean that we can lengthen the telomeres of a healthy person to make them immortal. It means something more limited and more important: perhaps we can treat rare diseases in which telomere shortening is a direct cause of bone-marrow, immune or pulmonary failure.
The difference is essential. Curing a short-telomere pathology is not the same as defeating aging. But it proves that one of the pieces of the biological clock is becoming manipulable.
The problem is that telomeres are only one piece. A cell with long telomeres may still have damaged DNA, deteriorated mitochondria, a disordered epigenome, misfolded proteins or altered inflammatory signals. Lengthening chromosome ends does not by itself restore youth.
Telomeres can delay an alarm. They do not rebuild the whole house.
Bibliography for this section
Telomere dysfunction in ageing and age-related diseases — Nature Cell Biology (2022)
Elixirgen Therapeutics: early results of ZSCAN4 gene therapy for telomere disorders (2025)
Gene therapy offers new hope for telomere diseases — Drug Discovery News
Second clue: artificial intelligence looks for patterns where the human eye cannot reach
Modern longevity no longer depends only on microscopes, cell cultures and mouse studies. It also depends on data. Huge amounts of data.
Genomic sequences. Proteomics. Metabolomics. Tissue images. Clinical histories. Epigenetic clocks. Inflammatory biomarkers. Drug-screening results. Exercise, sleep, glucose, microbiome and immune-response data. Aging is a network, and complex networks are precisely the kind of territory where artificial intelligence can detect relationships no researcher would see at a glance.
AI is being used in several directions. One is to discover new drugs or reposition existing ones. Another is to predict a person’s biological age from DNA-methylation patterns, retinal images, blood tests or proteomic profiles. Another is to design proteins or molecules capable of interacting with targets related to cellular repair.
AlphaFold transformed structural biology by predicting protein shapes with unprecedented accuracy. AlphaFold 3 expanded the problem to biomolecular complexes: proteins interacting with DNA, RNA, ligands and other molecules. That leap matters for longevity because many future therapies will depend on understanding highly specific molecular interactions: repair enzymes, inflammatory receptors, mitochondrial proteins, transcription factors or cell-signaling pathways.
Isomorphic Labs, born from the Google DeepMind environment, is working to turn these models into a drug-discovery platform. Its goal is to accelerate medicine. But if the biology of aging becomes a set of therapeutic targets, AI-assisted molecular-design tools will be decisive.
Longevity companies are also integrating AI into their platforms. NewLimit, Retro Biosciences, Calico, Altos Labs and others are exploring different aspects of cellular reprogramming, rejuvenating factors, epigenetic biology or massive cellular-data analysis. Some are highly opaque. Others publish partial advances. All share one idea: aging may not be understandable through small, linear experiments alone. Whole systems need to be mapped.
But AI does not eliminate biology. It can propose molecules. It can prioritize genes. It can find correlations. It can generate hypotheses. What it cannot do is turn a correlation into clinical safety. A model can detect a pathway associated with longevity. A human body may respond with inflammation, cancer, autoimmunity or failure in another tissue.
Artificial intelligence can accelerate the search. It cannot abolish the test.
The algorithm can find a key. The body decides whether it opens a door or a wound.
Bibliography for this section
Accurate structure prediction of biomolecular interactions with AlphaFold 3 — Nature (2024)
The Isomorphic Labs Drug Design Engine unlocks a new frontier — Isomorphic Labs (2026)
Third clue: rejuvenating a cell without erasing what it is
The most spectacular line in today’s longevity research is partial cellular reprogramming.
In 2006, Shinya Yamanaka showed that an adult cell could return to an embryo-like state by activating a set of genetic factors. That changed biology. If an adult cell could return to a pluripotent state, cellular identity was more plastic than previously believed.
But in longevity, the challenge is not to turn a skin cell into an embryonic cell. Inside an adult body, that would be extremely dangerous. A neuron must remain a neuron. A liver cell must remain a hepatocyte. A retinal cell must still belong to the retina. Rejuvenating without erasing identity demands extreme precision.
That is why researchers speak of partial reprogramming. The idea is to activate some Yamanaka factors — for example OSK or OSKM — for a controlled period in order to restore youthful gene-expression and methylation patterns without returning the cell to an undifferentiated state.
In animals, some results have been extraordinary. Mouse studies have shown tissue repair, improved regeneration and partial reversal of epigenetic markers. Work on the optic nerve showed that certain reprogramming programs could restore visual function in animal models. That path has led to one of the field’s most important milestones: Life Biosciences’ ER-100.
In January 2026, Life Biosciences announced FDA clearance to begin human studies with ER-100, an epigenetic-restoration therapy for optic neuropathies such as open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. In June 2026, the company announced that the first patient had been dosed in a phase 1 trial. It is one of the first human trials of a cellular-rejuvenation therapy based on partial epigenetic reprogramming.
The detail matters: the whole body is not being rejuvenated. Safety and tolerability are being tested in a localized indication, the eye, specifically cells related to the optic nerve. The eye is attractive because it is accessible, relatively isolated and allows functional changes to be measured with precision.
But its symbolic value is enormous. If an epigenetic-restoration therapy proves safe and shows any efficacy signal in humans, the whole field will change phase. It will move from preclinical promise to real experimental medicine.
The risk is also enormous. Too much reprogramming can cause loss of cellular identity, uncontrolled proliferation or tumors. Too little may do nothing. Reprogramming one tissue can alter signals that depend on the rest of the organism. Youth is not one instruction. It is coordination among thousands of instructions.
Rejuvenating a cell is difficult. Rejuvenating an organism without turning it into something else is much harder.
Bibliography for this section
In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming — Cell (2016)
Life Biosciences Pipeline: ER-100 and epigenetic restoration
Life Biosciences: first patient dosed with ER-100 in phase 1 (2026)
Longevity startup doses first human in bid to reverse age-related sight loss — WIRED (2026)
Altos Labs — cellular rejuvenation research
Fourth clue: killing old cells can rejuvenate tissues, but it is not always convenient
Another strategy is to eliminate senescent cells.
A senescent cell is a cell that has stopped dividing because of damage, stress or telomere shortening, but has not disappeared. For a long time, senescence was viewed as a protective mechanism: a way to prevent damaged cells from continuing to divide and becoming cancerous.
That remains true. But with age, many senescent cells accumulate and begin to release inflammatory signals, enzymes and molecules that alter the tissue. They become small factories of deterioration. That is why they are informally called zombie cells: they do not function properly, but they keep influencing their environment.
Senolytics seek to destroy them selectively. Some compounds, such as dasatinib combined with quercetin, fisetin and other candidates, have shown interesting effects in animal models and preliminary human studies for specific conditions. Immunological or genetic strategies are also being investigated to recognize and eliminate senescent cells.
The logic is attractive: if senescent cells pollute the tissue, clean them out.
But senescence is not only biological garbage. It also participates in wound healing, embryonic development and tumor suppression. Eliminating all senescent cells indiscriminately could impair repair, alter normal signals or remove barriers against cancer.
Moreover, not all senescent cells are the same. A senescent cell in adipose tissue does not necessarily behave like a senescent cell in the brain, lung or kidney. Some secrete aggressive inflammatory profiles. Others may have useful transient functions. The future of senolytics lies in precise interventions by tissue, cellular state and disease.
The appeal of this pathway is that it does not try to make every cell immortal. It does the opposite: it accepts that some cells must die so the organism can live better.
Longevity does not always mean preventing death. Sometimes it means allowing what is already damaging the whole to die.
Bibliography for this section
Senescent cells as a target for anti-aging interventions — Review (2025)
Targeting Cellular Senescence in Aging and Disease — Aging and Disease
Fifth clue: perhaps we do not need to rejuvenate the whole body, only its organs
Complete biological immortality may be very far away. But there is a more practical path: repairing or replacing the critical pieces.
We already live in that world. Transplants, prostheses, pacemakers, valves, intraocular lenses, dialysis, stents, cochlear implants and insulin pumps. Modern medicine already prolongs life by replacing functions that once meant condemnation.
The novelty is that donor organs are beginning to be treated as systems that can be optimized before entering another body. Ex vivo perfusion keeps an organ alive outside the organism through machines that circulate fluids, oxygen, nutrients and drugs. That allows physicians to evaluate the organ, partially repair it and apply therapies before transplantation.
Recent reviews in Nature Communications and Cell Stem Cell raise a powerful possibility: rejuvenating older or suboptimal donor organs in order to expand the number of available organs. If ischemia-reperfusion damage, inflammation, senescence or vascular deterioration can be reduced, organs that would be discarded today could become useful grafts.
This approach changes the problem. The body is no longer a closed unit. It is a set of maintainable systems, and some can be treated outside the body.
3D bioprinting, organoids, cultivated tissues and xenotransplantation are also advancing. Genetically edited pig organs have already reached experimental human transplants, with results still limited but important. Each advance reduces the idea that our biological pieces are irreplaceable.
However, this path encounters an obvious limit: the brain.
We can imagine a replaced heart, a new kidney, a regenerated liver or an artificial cornea. But we cannot replace the cerebral cortex without altering memories, personality and subjective continuity. The brain is not just a piece. It is where the story of the person is organized.
Organ repair can delay natural death for a very long time. But while the brain remains vulnerable to aging, the question of identity will remain intact.
We can change many pieces of the ship. The problem begins when the damaged piece is the captain.
Bibliography for this section
Anti-aging strategies and ex vivo organ rejuvenation — Cell Stem Cell (2026)
A Brain-Computer Interface Company Is Getting Into Organ Preservation — WIRED
Sixth clue: longevity drugs try to modulate ancient pathways
Not every longevity pathway looks like science fiction. Some are humbler, and for that reason may be closer.
Rapamycin, metformin, mTOR inhibitors, AMPK modulators, calorie-restriction mimetics and interventions on NAD+ explore a common idea: aging partly depends on metabolic pathways conserved by evolution. Nutrition, growth, repair, cellular stress, autophagy, inflammation and energy form an interconnected circuit.
Caloric restriction extends life in many organisms by modifying growth, repair and survival signals. Rapamycin, for example, acts on mTOR, a pathway regulating growth and metabolism. In animal models, modulation of this pathway has shown effects on longevity. In humans, the current goal is to study whether it can improve immune function, reduce inflammation or delay specific pathologies.
Metformin, a classic drug for type 2 diabetes, has generated huge interest because of possible associations with lower risk of some age-related diseases, although the evidence does not allow it to be treated as an anti-aging pill. The TAME trial, designed to study whether metformin can delay multiple age-associated diseases, symbolizes an important conceptual change: attempting to treat aging as a modifiable factor.
Popular supplements and molecules such as NAD+, NMN, resveratrol and spermidine also appear. Some have plausible biological foundations. Others are surrounded by excessive marketing. The longevity field has a constant problem: the boundary between legitimate research and commercial promise is very porous.
That is why the correct question is not whether a molecule “rejuvenates.” The question is: in which organism, at what dose, for how long, with which biomarkers, with which adverse effects, in which tissue and with which real clinical outcome?
Pharmacological longevity may not produce immortals. But it could produce something just as important: more years of functional life, less frailty, less inflammation and a compression of morbidity, meaning deterioration is concentrated at the end instead of occupying decades.
The most realistic medicine of longevity does not promise to live forever. It promises to arrive later at deterioration.
Bibliography for this section
XPRIZE Healthspan: therapeutic solutions to restore muscle, cognition and immunity
$101m longevity research prize aims to “shatter the limits” on ageing — The Guardian (2025)
TAME Trial — American Federation for Aging Research
Seventh clue: freezing is not resurrection
Cryonics occupies a strange place in the search for immortality. It does not try to cure aging now. It tries to preserve the body or brain after legal death in the hope that future technology can repair the damage, reverse the cause of death and restore the person.
The idea turns death into a waiting period.
Scientifically, it remains a speculative bet.
So far, cryonics has not brought any human being back to life. Current techniques use vitrification to minimize ice-crystal formation, but the challenge is not merely preserving a body. One would also have to repair the original cause of death, reverse cellular damage caused by the process, eliminate cryoprotectant toxicity, avoid thermal fractures and restore the normal function of complex organs such as the brain.
Advances in tissue cryopreservation are real and should not be mocked. Some experiments have shown that certain microscopic structures can be preserved in remarkable detail. In 2026, news appeared about recovered activity in mouse brain tissue after deep freezing. But the nuance is essential: brain tissue is not a whole brain; cellular activity is not memory; local functional recovery is not the resurrection of a mind.
A human brain contains synaptic architecture, molecular states, chemical gradients, glial cells, vascularization, metabolism, distributed memory and dynamic activity patterns. Preserving it with enough fidelity, keeping it for decades or centuries, warming it homogeneously, repairing all injuries and reactivating consciousness remains beyond our capabilities.
Cryonics is a bet on the future. Perhaps rational for someone who believes a small probability is better than none. Perhaps a modern form of hope. Perhaps a sophisticated technological illusion.
But it is not immortality.
Freezing a library does not guarantee that anyone will read its books again.
Bibliography for this section
Scientists revive activity in frozen mouse brains for the first time — Nature (2026)
Alcor Life Extension Foundation — information on cryonics
Eighth clue: copying a mind may not be saving a life
The most radical form of immortality does not try to preserve the body. It tries to preserve information.
If one day we could scan a brain with sufficient precision, reconstruct its structure, simulate its dynamics and reproduce its memories, emotions, habits and personality on a digital substrate, perhaps we could create a functional copy of a mind.
This is called mind uploading, whole-brain emulation or mental transfer.
The technical problem is enormous. We do not know what level of detail would be necessary. It is not enough to know neuronal connections. We would need to understand synaptic weights, cellular states, neuromodulators, electrical activity, plasticity, metabolism, glia, body, hormones and perhaps other levels we do not yet know how to identify as relevant.
But the philosophical problem is harder.
Even if a digital copy spoke like you, remembered your childhood, recognized your children and insisted that it was you, would you continue to experience that existence?
Or would you have died leaving behind a convincing replica?
Here the difference between copy and continuity appears. From outside, a perfect copy might look like survival. From inside, perhaps not. If the transfer destroys the original brain, it could be replacement. If it does not destroy it, there would be two versions. If there are two versions, neither can be “the same” in an exclusive sense.
Digital immortality could solve the persistence of an observable identity. But perhaps not the continuity of a consciousness.
This is the frontier where science crosses philosophy. Brain emulation can, in principle, reproduce functions. But we do not know whether reproducing functions is equivalent to transferring subjective experience.
This connects with the connectome problem: even if we could scan all neuronal connections, we would still need to understand dynamic activity, synaptic chemistry, plasticity, the role of glial cells and subjective experience. That is why mind transfer depends not only on storing information, but on knowing exactly what information makes a mind remain that mind. Could We Copy a Human Mind? What a Fly’s Brain Teaches Us
A copy can continue your story. The question is whether you wake up inside it.
Bibliography for this section
Whole Brain Emulation: A Roadmap — Future of Humanity Institute
Personal Identity — Stanford Encyclopedia of Philosophy
Existential meaning and afterlife beliefs predict mind upload approval — PLOS ONE / PMC
Ninth clue: living forever young does not eliminate every problem
Let us suppose that part of the dream comes true.
Let us suppose we manage to delay aging, repair organs, eliminate senescent cells, modulate metabolic pathways, restore epigenetic functions and reduce many degenerative diseases.
Even then, we would not have eliminated death.
Accidents. Violence. Catastrophes. New diseases. Technical errors. Brain damage. Suicide. Wars. Environmental collapses. Cosmic risks.
A biologically rejuvenated humanity would remain vulnerable. Real immortality would require far more than medicine. It would require permanent protection, controlled environments, backups, redundancy, surveillance, absolute risk prevention and perhaps migration to digital substrates.
But a life without risk raises another question.
Would it still be human?
Mortality destroys us and organizes our desires. Urgency, memory, love, loss, grief, ambition, parenthood, forgiveness, work and renunciation are all crossed by finitude.
That does not mean dying is good. It means that removing death would not only extend life; it would change the structure of human experience.
It would also be a political problem. If living two hundred years in health became possible, who would have access? The rich first? The most advanced countries? Technological elites? Leaders? The young before the old? The sick before the healthy?
A society in which some do not die can become a society in which some never make room. They would occupy resources, positions, fortunes, institutional memory and influence for centuries.
Death has always been an individual tragedy. But it has also functioned as a brutal mechanism of collective renewal.
Eliminating death would force us to invent a new form of succession.
Bibliography for this section
Human Enhancement — Stanford Encyclopedia of Philosophy
XPRIZE Healthspan — debate on healthy longevity and accessibility
Tenth Clue: What if this generation were the last to grow old?
So far, we have explored the main lines of research that aim to delay or even reverse aging. They all exist. They are all being actively studied. Some have already reached human clinical trials. The question is unavoidable.
Are we witnessing the beginning of a medical revolution comparable to the discovery of antibiotics or vaccines?
Not all researchers give the same answer.
Part of the scientific community remains cautious. Aging is still one of the most complex biological processes we know, and we still do not fully understand how the many mechanisms that drive it interact. Delaying a specific disease is very different from controlling the entire aging process of an organism.
However, other researchers believe that the pace of recent advances is changing the landscape far faster than most of us imagine.
Among those who have contributed most significantly to this shift are scientists such as Carlos López-Otín, one of the authors of the influential paper The Hallmarks of Aging, which defined the principal biological mechanisms involved in aging; María A. Blasco, an internationally recognized expert on telomeres and telomerase; Manuel Serrano, a pioneer in the study of cellular senescence; and Juan Carlos Izpisúa Belmonte, whose work on cellular reprogramming and rejuvenation in animal models has shown that some aging-related processes can be reversed under specific experimental conditions.
Building on these advances, some researchers argue that aging could eventually cease to be an unavoidable process and become, at least in part, a treatable condition. One of the best-known proponents of this view is gerontologist Aubrey de Grey, who argues that aging could be addressed by periodically repairing the cellular damage that accumulates before it develops into disease.
This vision has also been brought to a wider audience by authors such as José Luis Cordeiro, one of the best-known advocates of radical longevity in the Spanish-speaking world. Cordeiro argues that aging should be regarded as a treatable disease and that humanity may eventually reach what some call longevity escape velocity: the point at which medical advances add more than one year of healthy life for every year that passes. If that threshold were ever reached, life expectancy would begin to increase faster than time itself. His work has played an important role in bringing the debate about longevity from specialist scientific circles into the public conversation.
Alongside them, figures such as Elizabeth Parrish, founder of BioViva, have helped popularize gene therapy research aimed at extending healthy lifespan through experimental interventions performed on themselves. Although these initiatives have attracted considerable media attention, they remain controversial and do not yet constitute conclusive clinical evidence.
In contrast, many scientists continue to advocate greater caution. They point out that numerous treatments that showed promise in animals have failed in humans, and that every new breakthrough tends to reveal biological challenges we did not previously understand.
What is remarkable is that, for the first time in history, the debate is no longer about whether aging can be modified, but about how much it can be modified and how far these advances may ultimately go.
Only a few decades ago, this discussion belonged almost entirely to the realm of science fiction. Today it is part of scientific conferences, clinical trials, biotechnology companies, and some of the largest private investments in biomedical research anywhere in the world.
Perhaps no one can say with certainty that we will one day defeat aging. But it is no longer reasonable to claim that doing so is impossible.
References for this section
José Luis Cordeiro — Official website
The Death of Death — José Luis Cordeiro & David Wood
Longevity Escape Velocity Foundation
SENS Research Foundation — Aubrey de Grey
BioViva Science — Elizabeth Parrish
The Hallmarks of Aging — López-Otín et al. (Cell, 2013)
Table: current science versus the dream of immortality
| Pathway | Promise | Current scientific state | Main risk |
|---|---|---|---|
| Telomeres | Extend cellular replicative life | Experimental therapies for telomere disorders; not yet applicable to general longevity | Cancer and uncontrolled proliferation |
| AI and genomics | Discover anti-aging targets and drugs | Advanced models such as AlphaFold 3 and AI molecular design; slow clinical validation | Confusing correlation with causality |
| Epigenetic reprogramming | Restore youthful cellular states | Early localized human trials such as ER-100 in optic neuropathies | Loss of cellular identity and tumors |
| Senolytics | Eliminate harmful senescent cells | Promising in animal models and preliminary trials | Removing cells with useful functions |
| Organ rejuvenation | Repair organs before transplantation | Ex vivo perfusion and anti-inflammatory/senotherapeutic strategies in development | Does not solve systemic or brain aging |
| Cryonics | Preserve the body or brain for future medicine | Tissue cryopreservation progressing; no resurrection of whole brains | Irreversible damage and no demonstrated continuity |
| Mind uploading | Transfer the mind to a digital substrate | Connectomics and partial simulations; human brain remains out of reach | The copy may not be subjective continuity |
So, could we defeat death?
It depends on what defeating means.
If it means never dying, no existing technology can promise that today.
If it means living much longer in good health, the answer is more open. Real paths exist: senolytics, epigenetic reprogramming, gene therapies, regenerative medicine, preserved organs, inflammation control, molecular repair, artificial intelligence applied to drug discovery and a growing understanding of aging.
If it means preserving a mind beyond the body, we enter a much more uncertain territory. Preserving a brain is not waking it up. Copying a mind does not prove continuity. Simulating a person does not guarantee that person is still there.
Science can delay death. It can make it less early. It can make it less unjust. It may even change its definition.
But the final question is not only technical.
It is human.
If we could live for centuries, would we still choose in the same way? If we could rejuvenate, would we ever accept aging? If we could copy ourselves, would we accept that a copy replace us? If no one had to die, what would happen to love, grief, memory, power and meaning?
The search for immortality is not only about defeating time.
It is about discovering what part of us deserves to continue.
And what price we would be willing to pay to preserve it.
Is humanity ready to defeat death?
The final question is not only whether we could live much longer. It is whether we would know how to live in a civilization where death no longer ordered time.
Radical longevity would alter population, family, work, inheritance, politics and the very idea of generation. If human beings could live two hundred, five hundred or a thousand years, when would a life be considered complete? When would power be transferred? When would someone make room for those who come after?
Families would change profoundly. Ten, twenty or thirty generations could coexist at the same time. Parenthood would no longer be tied to a limited biological window. Inheritance would lose its meaning if the original owners never disappear. Love, grief and family memory would have to reorganize around much longer bonds, perhaps also more fragile ones.
Society would not remain intact either. A rejuvenation therapy available only to a minority would create a more radical division than any known inequality: mortals and immortals, bodies that expire and bodies kept young. If, on the contrary, it were available to everyone, the planet would face another pressure: growing population, consumption, reproductive limits and new forms of political regulation.
There is also a much more tangible problem: space and resources. Even if humanity eliminated aging, it would still need food, water, energy, raw materials and somewhere to live. If each generation remained on Earth while new people continued to be born, pressure on the planet would grow to levels difficult to imagine. Overpopulation would stop being a demographic concern and become a physical problem.
Perhaps the solution would involve limiting birth rates, expanding into space or building artificial habitats capable of housing millions of people. But each alternative would open new dilemmas. Who would have the right to have children? Who would decide when a population has reached its limit? How would the energy consumption of a civilization where no one dies be sustained? Immortality would not eliminate humanity’s problems. It would change their nature.
Culture would change too. Death, with all its cruelty, has functioned as a mechanism of renewal. It forces people to yield their place. It interrupts fortunes, leaderships, dogmas and systems of power. A humanity without natural death might become wiser, but also more rigid. More prudent, but perhaps less able to let the new be born.
In that sense, defeating death would not only be a medical victory. It would be a civilizational mutation. Humanity would have to decide how to keep living and which limits to preserve so life does not become an indefinite accumulation of time, power and memory.
That is one of the central conflicts of the Eidos universe. Survival is not enough. A civilization can preserve its individuals and still lose something essential if it does not understand the role that fragility, succession, grief and finitude played in the construction of the human.
The question may not be whether humanity can defeat death. The question is whether it could do so without destroying the balance that gave meaning to being alive.
What matters in EIDOS
In Eidos, the search for continuity is born from an extreme situation: preserving the human when the biological and planetary substrate no longer guarantees a future.
That is why the Great Transfer is not only a technology. It is a civilizational question.
If identity resides in the body, any migration would be a loss. If it resides in the continuity of the pattern, perhaps it can survive a change of substrate. If it depends on a subjective experience that we do not know how to measure, perhaps we will never be able to prove from outside whether someone has continued or whether only a perfect copy has appeared.
Real science is moving toward therapies that can delay aging, rejuvenate tissues, preserve organs and better understand the brain. But each advance opens a new crack. Life can be extended. Youth can be manipulated. Organs can be repaired. The mind may one day be modeled.
What we do not know is whether, by removing death, we leave intact what life meant.
Perhaps the real question is not whether we can live forever. Perhaps it is another: would we still be human if we succeeded?
Bibliography for this section
EIDOS — official website of the novel’s universe
Comments